BioCentury
ARTICLE | Politics, Policy & Law

On the other hand . . .

June 11, 2007 7:00 AM UTC

Although the Cleveland Clinic's Steven Nissen argued in Congress last week that publishing his Avandia meta-analysis was his "scientific, moral - my ethical - obligation," there is at least one instance when the researcher felt it was appropriate to go directly to FDA before submitting his research to peer review.

In 2005, Nissen took credit for torpedoing the approval of Pargluva muraglitazar, an oral anti-diabetes compound from Bristol-Myers Squibb Co. (BMY, New York, N.Y.) that had received an 8-1 recommendation for approval from FDA's Endocrinologic and Metabolic Drugs Advisory Committee. ...